Citations

Clear

941 citation(s) found for "Tefferi, A".

Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia
Lanino, Luca , Hunter, Anthony M. , Gagelmann, Nico, Robin, M., Dall'Olio, Daniele , Flamigni, Alice, Gurnari, Carmelo, Wang, Yu‐Hung , Pleyer, Lisa , Xicoy, B., Montalban-Bravo, Guillermo, Shih, Lee-Yung, Alsugair, Ali, Gregorio, Caterina, Platzbecker, Anne Sophie, Sallman, David A., Fariselli, Piero, Garcia-Manero, Guillermo, Platzbecker, U, Solé, Francesc Gessé, Díez-Campelo, María, Maciejewski, Jaroslaw, Bejar, Rafael, Thol, Felicitas, Kroger, N., Fenaux, Pierre, Sanz, G. F., Kordasti, S., Santini, Valeria, Zeidan, Amer M., Komrokji, Rami S., Haferlach, Torsten, Germing, Ulrich, Castellani, Gastone, D'Amico, Saverio, Patnaik, M., Ieva, F., Tefferi, Ayalew, Padron, Eric , Porta, Matteo Giovanni Della, Alliance, for the iCPSS, Haque, Tamanna, Abdel-Wahab, Omar, Geissler, Klaus, Bataller, Alex, Bazinet, Alexandre , Meggendorfer, Manja , Quintavalla, Mirco, Bruseghini, Alessandro , Carota, Luciana , Dall'Olio, Lorenzo, Travaglino, Erica , Zamora, Lurdes López, Quintela, David, Jerez, Andrés , Cornejo, Elena, Martín, Paloma García, Díaz-Beyá, Marina, Pita, Alejandro Avendano, Roldán, Verónica , Suarez, Dolly Viviana Fiallo, Velasco, Estefania Cerezo, Calabuig, Marisa , Such, Esperanza, Castilla-Llorente, Cristina, Bulabois, Claude Eric, Souchet, Laëtitia, Bernardi, Massimo, Chiusolo, Patrizia, Borin, Lorenza, Follo, Matilde Yung, Consagra, Angela , Passamonti, Francesco, Diral, Elisa , Vucinic, Vladan, Bergonzi, Gregorio Maria , Hou, Hsin-An, Russo, Antonio, Tentori, Cristina Astrid , Buizza, Alessandro , Ferrari, Ivan, Matteo, Maria Di, Crespi, Alessandra, Figini, Giulia , Delponte, Camilla, Zampini, Matteo, Riva, Elena, Delleani, Mattia , Iascone, Eleonora, Ficara, Francesca , Ventura, Denise, Pinocchio, Nicole, Santoro, Armando, Kiwan, Ahmad , Ali, Najla H. Al, Zeidan, Amer M. , Robin, Marie , Dall’Olio, Daniele , Riva, Elena , Gagelmann, Nico , Robin, Marie , Sala, Claudia , Gurnari, Carmelo , Wang, Yu-Hung , Shih, Lee‐Yung , Alsugair, Ali , Fathima, Saubia , Gregorio, Caterina , Rollo, Cesare , Platzbecker, Anne Sophie , Asti, Gianluca , Itzykson, Raphael , Sallman, David A , Fariselli, Piero , Kern, Wolfgang , Garcia-Manero, Guillermo , Platzbecker, Uwe , Solé, Francesc , Diez-Campelo, Maria , Maciejewski, Jaroslaw P , Bejar, Rafael , Thol, Felicitas , Savona, Michael R , Sanz, Guillermo F , Kordasti, Shahram , Santini, Valeria , Zeidan, Amer M , Komrokji, Rami S , Castellani, Gastone , D'Amico, Saverio , Patnaik, Mrinal , Ieva, Francesca , Solary, Eric , Padron, Eric , Della Porta, Matteo Giovanni , Buizza, Alessandro , Ficara, Francesca , Lanino, Luca , Gagelmann, Nico , Gurnari, Carmelo , Xicoy, Blanca , Montalban‐Bravo, Guillermo , Fathima, Saubia , Gregorio, Caterina , Palomo, Laura , Itzykson, Raphaël , Sallman, David A. , Kern, Wolfgang , Garcia‐Manero, Guillermo , Platzbecker, Uwe , Solé, Françesc , Díez‐Campelo, María , Thol, Felicitas , Kröger, Nicolaus , Savona, Michael R. , Fenaux, Pierre , Sanz, Guillermo , Santini, Valeria , Fontenay, Michaëla , Komrokji, Rami S. , Haferlach, Torsten , Germing, Ulrich , Solary, Éric , Tefferi, Ayalew , Haque, Tamanna , Bataller, Alex , Sauta, Elisabetta , Sanavia, Tiziana , Dall'Olio, Lorenzo, Díaz‐Beyá, Marina , Roldan, Veronica, Fiallo, Dolly Viviana , Such, Esperanza , Castilla‐Llorente, Cristina , Bulabois, Claude‐Eric , Awada, Hussein , Chiusolo, Patrizia , Curti, Antonio , Giaccone, Luisa , Finelli, Carlo , Casetti, Ilaria Carola , Onida, Francesco , Passamonti, Francesco , Vučinić, Vladan , Voso, Maria Teresa , Hou, Hsin-An, Chou, Wen‐Chien , Yao, Chi‐Yuan , Lin, Chien‐Chin , Tien, Hwei‐Fang , Campagna, Alessia , Ubezio, Marta , Todisco, Gabriele , Maggioni, Giulia , Matteo, Maria Di, Pesce, Francesco , Zampini, Matteo , Crisafulli, Laura , Ventura, Denise , Pinocchio, Nicole , Brindisi, Matteo , VanOudenhove, Jennifer , Ali, Najla H. Al, Graubert, Timothy Aaron , Thota, Swapna , Griffiths, Elizabeth A.

Mayo Clinic

Journal of Clinical Oncology | March 27, 2026 | Volume: 44 | Issue: 17 | Pages: 1608-1623

10.1200/jco-25-02116 | PMID 41894646 Get It

PURPOSE Chronic myelomonocytic leukemia (CMML) is a rare myeloid neoplasm characterized by clinical heterogeneity and is associated with poor outcomes. To date, limited molecular information has been incorporated into disease classification and risk stratification. We aimed to integrate genomic features into the clinical decision-making process for CMML. PATIENTS AND METHODS We analyzed a retrospective cohort of 3013 patients with CMML (training set) and a prospective population of 516 patients (validation set). Using an innovative framework for multimodal data analysis, we developed molecular-based disease taxonomy and prognostication. RESULTS Unsupervised clustering identified nine entities with distinct genomic features and outcomes ( P < .001), including splicing machinery, transcription factors, signal transduction and tyrosine kinase pathways aberrations, and high-risk molecular signatures. Notably, 15% of patients showed molecular/clinical overlap with other myeloid neoplasms. We integrated molecular and clinical information to build the international CMML Prognostic Scoring System (iCPSS), incorporating mutations in nine genes together with hematologic parameters and cytogenetic abnormalities. The iCPSS identified five groups with distinct probability of overall and leukemia-free survival in both training and validation cohorts ( P < .001), outperforming existing prognostic models. Importantly, 55% of patients were reassigned to higher or lower risk groups by the iCPSS. Decision analysis demonstrated that iCPSS could refine the optimal timing of allogeneic transplantation at the individual level; compared with conventional prognostic tools, iCPSS-based decision modeling changed transplantation strategy in 31% of cases, resulting in a significant gain-in-life expectancy for eligible patient population ( P < .001). A federated learning platform was implemented to enable continuous, privacy-preserving model update across multiple centers. CONCLUSION Molecular information improves CMML classification and prognostication, supports more effective clinical decision making, and potentially refines the design of clinical trials.
Thrombosis in primary myelofibrosis: the influence of cohort composition and disease biology
Barbui, Tiziano , Stefano, Valerio De, Tefferi, Ayalew, Vannucchi, Alessandro M. , Stefano, Valerio De , De Stefano, Valerio , Tefferi, Ayalew , Vannucchi, Alessandro M , Tefferi, Ayalew

Mayo Clinic

Blood Advances | February 12, 2026 | Volume: 10 | Issue: 7 | Pages: 2521-2524

10.1182/bloodadvances.2026019668 | PMID 41678834 Get It

Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic Leukemia
Montalban-Bravo, Guillermo, Wu, Chong , Rodríguez‐Sevilla, Juan José , Wei, Yue , Chien, K., Bouligny, Ian , Kanagal‐Shamanna, Rashmi , Li, Ziyi , Natu, Anuya , Bazinet, Alexandre , Hammond, Danielle E., Bataller, Alex, Borthakur, Gautam, Short, Nicholas J., DiNardo, Courtney D., Kadia, Tapan M., Ravandi, Farhad, Daver, Naval, Pemmaraju, Naveen, Jabbour, Elias, Issa, Ghayas C., Wang, Sa A., Patel, Keyur P. , Tang, Guilin, Medeiros, L. Jeffrey, Finke, Christy M. , Al‐Kali, Aref , Alkhateeb, Hassan, Gangat, Naseema, Mangaonkar, Abhishek A., Román, David , Arenillas, Leonor , Tefferi, Ayalew, Kantarjian, Hagop M., Garcia-Manero, Guillermo, Calvo, Xavier , Patnaik, Mrinal M. , Loghavi, Sanam, Kantarjian, Hagop M. , Bravo, Guillermo Montalban , Chien, Kelly , Gurney, Mark , Bazinet, Alexandre , Hammond, Danielle , Bataller, Alex , Borthakur, Gautam , Short, Nicholas , DiNardo, Courtney , Kadia, Tapan M , Ravandi, Farhad , Daver, Naval , Pemmaraju, Naveen , Jabbour, Elias , Issa, Ghayas , Wang, Sa A , Patel, Keyur P , Tang, Guilin , Medeiros, L Jeffrey , Lasho, Terra L , Finke, Christy M , Al-Kali, Aref , Csizmar, Clifford , Alkhateeb, Hassan B , Gangat, Naseema , Mangaonkar, Abhishek A. , Roman-Bravo, David , Arenillas, Leonor , Tefferi, Ayalew , Kantarjian, Hagop , Garcia-Manero, Guillermo , Calvo, Xavier , Patnaik, Mrinal , Loghavi, Sanam , Kanagal-Shamanna, Rashmi , Rodríguez-Sevilla, Juan José , Montalban‐Bravo, Guillermo , Chien, Kelly S. , Gurney, Mark E. , Hammond, Danielle , Borthakur, Gautam , Short, Nicholas J. , DiNardo, Courtney D. , Kadia, Tapan M. , Daver, Naval , Pemmaraju, Naveen , Jabbour, Elias , Wang, Sa A. , Tang, Guilin , Medeiros, L. Jeffrey , Lasho, Terra L. , Csizmar, Clifford M. , Alkhateeb, Hassan B. , Gangat, Naseema , Mangaonkar, Abhishek A. , Tefferi, Ayalew , Garcia‐Manero, Guillermo , Loghavi, Sanam

Mayo Clinic

Blood Cancer Discovery | January 26, 2026 | Volume: 7 | Issue: 3 | Pages: 414-430

10.1158/2643-3230.bcd-25-0264 | PMID 41587375 Get It

Abstract Recent updates to monocyte count thresholds recognize oligomonocytic chronic myelomonocytic leukemia (OM-CMML) as an early form of CMML. However, the clinical validity of these changes remains uncertain without incorporating biological and genomic factors. In this study, we analyzed a cohort of 911 patients (249 with OM-CMML, 359 with overt CMML, and 303 with myelodysplastic syndromes) using unsupervised clustering to evaluate the role of genomic determinants in refining CMML diagnosis. Our findings show that CMML molecular signatures (biallelic TET2 mutations or SRSF2-TET2 comutations) are linked to a distinct transcriptome, monocytic bias, classical monocytosis, and a higher risk of progression to overt CMML in OM-CMML cases. We developed a weighted genomic model and diagnostic workflow showing that combining genomic signatures with bone marrow monocyte frequencies in OM-CMML more accurately predicts progression to overt CMML. These findings support integrating genomic determinants and our clinic-ready diagnostic workflow into the CMML diagnostic framework to improve accuracy. Significance: Through comprehensive clinical and genomic profiling of a large patient cohort, alongside immunophenotypic and transcriptional cellular analyses, this study provides evidence that incorporating genomic determinants into the diagnostic criteria for OM-CMML improves diagnostic accuracy and refines the identification of early-stage CMML, thereby preventing misclassification.
Post‐ FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Perip
Tefferi, Ayalew, Abdelmagid, Maymona, Palmer, Jeanne , Al‐Kali, Aref, Yi, Cecilia Y. Arana , Matin, Aasiya, Alkhateeb, Hassan B., Badar, Talha , Bashir, Yassin, Reichard, Kaaren K. , He, Rong , Pardanani, Animesh , Gangat, Naseema, Tefferi, Ayalew , Al-Kali, Aref , Gangat, Naseema , Badar, Talha , Tefferi, Ayalew , Al‐Kali, Aref , Yi, Cecilia Arana , Matin, Aasiya , Alkhateeb, Hassan B. , Gangat, Naseema

Mayo Clinic

American Journal of Hematology | January 8, 2026 | Volume: 101 | Issue: 3 | Pages: 570-576

10.1002/ajh.70203 | PMID 41504170 Get It

Navigating prognostic stratification and approach to TP53-mutated myeloid neoplasms
Badar, Talha , Tefferi, Ayalew, Gangat, Naseema, Badar, Talha , Tefferi, Ayalew , Gangat, Naseema

Mayo Clinic

Current Opinion in Hematology | January 7, 2026 | Volume: 33 | Issue: 2 | Pages: 51-57

10.1097/moh.0000000000000906 | PMID 41496439 Get It

Purpose of review TP53- mutated ( TP53 -MT) myeloid neoplasms (MN) represent one of the most challenging disease subsets due to their distinct pathobiology, frequent association with therapy-related disease, chemo-resistant phenotype, and dismal outcomes. The prognostic impact of TP53 -MT is not uniform and is influenced by disease state, allelic burden, and co-occurring cytogenetic and molecular aberrations that shape disease trajectory. While current prognostic models incorporate TP53 status, they incompletely capture the heterogeneity within TP53 -MT MN. Therapeutic options remain limited, with allogeneic stem cell transplantation being the only intervention offering long-term survival in selected patients. Recent findings Novel approaches, including p53 reactivators and anti-CD47 antibodies in combination with standard-of-care therapies, have been explored; however, none has yet transformed the natural history of TP53 -MT MN. Summary This review highlights the current understanding of TP53 -MT MN, evolving strategies of prognostic stratification and propose a practical framework for clinical management. We further discuss the critical unmet need for collaborative, biologically informed clinical trials to improve outcomes of this challenging disease entity.
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients
Gangat, Naseema, Fathima, Saubia , Rokach, Lior , Ghosoun, Nour, Rezasoltani, Mahsa , Ilyas, Rimal, Alsugair, Ali, McCullough, Kristen , Abdelmagid, Maymona, Al‐Kali, Aref , Alkhateeb, H., Begna, Kebede H. , Mangaonkar, Abhishek, Matin, Aasiya, Hefazi, Mehrdad T., LITZOW, Mark R., Shah, Maleeha, Patnaik, Mrinal M. , Pardanani, Animesh, Foran, James M. , Palmer, Jeanne , Punwani, Nathan , Sproat, Lisa, Khera, Nandita , Tefferi, Ayalew, McCullough, Kristen B , Fathima, Saubia , Ghosoun, Nour, Ilyas, Rimal, Alkhateeb, Hassan B. , Mangaonkar, Abhishek A. , Matin, Aasiya , Saliba, Antoine N. , Hefazi, Mehrdad , Litzow, Mark R. , Hogan, William J , Shah, Mithun V , Pardanani, Animesh , Badar, Talha , Murthy, Hemant S. , Sproat, Lisa, Yi, Cecilia Arana , Tefferi, Ayalew , Gangat, Naseema

Mayo Clinic

No container title available | December 22, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8233179/v1 Get It

Abstract The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary ( de novo ) or secondary acute myeloid leukemia (AML) remains uncertain. In the current study, we retrospectively examined outcomes of 600 patients with newly diagnosed AML treated with CPX-351 (N = 112) or Ven-HMA (N = 488). AML subtypes included de novo (46%), post-myelodysplastic syndrome (MDS) (19%), post-myeloproliferative neoplasm (MPN) (12%), post-MDS/MPN (6%), therapy-related (17%) and AML with myelodysplasia-related genetic abnormalities (AML-MR; 46%). Patients receiving CPX-351 were younger (median 65 vs. 73 years; p < 0.01), predominantly female (50% vs. 38%; p = 0.02), more likely to have secondary AML (68% vs. 51%; p < 0.01), and less likely to harbor NPM1 MUT (5% vs. 12%; p = 0.02). Rates of complete response with or without count recovery (CR/CRi) were comparable between CPX-351 and Ven-HMA (55% vs. 60%; p = 0.30), including in AML-MR (60% vs. 63%; p = 0.70). Ven-HMA use was associated with fewer infectious complications (62% vs. 83%; p < 0.01) and yielded higher CR/CRi rates in males (60% vs. 45%; p = 0.04), de novo AML (68% vs. 50%; p = 0.03), and in the presence of STAG2 MUT (86% vs. 44%; p = 0.02), or CEBPA MUT (88% vs. 50%; p = 0.03). Overall survival censored for transplant, was similar (median 10 vs. 13 months; p = 0.90), with Ven-HMA being superior in post-MDS AML (median 12 vs. 7 months; p = 0.02) and CPX-351 in the presence of SF3B1 MUT (not reached vs. 14 months; p < 0.01). Our findings suggest that Ven-HMA is as effective and less toxic than CPX-351 in newly diagnosed AML, including AML-MR, despite selection of younger, fitter patients for CPX-351.
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study
Yasin, Irfan , Stengel, Anna , Shao, Haipeng , Kaur, Amandeep , Patwardhan, Pranav Pramod , Bailey, Nathanael G. , Inamdar, Kedar , Patel, Anand , Pandiri, M, Sojitra, Payal , Tariq, Hamza , Pan, Zenggang , Wiredja, Danica , Tjota, Melissa Y. , Segal, Jeremy , Chang, Hong , Sallman, David A. , Tefferi, Ayalew , Badar, Talha , Perry, Anamarija M. , Haferlach, Claudia, Patwardhan, Pranav P , Tefferi, Ayalew , Badar, Talha , Venkataraman, Girish , Patel, Anand , Shao, Haipeng, Mason, Emily F. , Ghosh, Sharmila , Zhang, Jingjing , Wang, Peng , Arber, Daniel A. , Haferlach, Claudia , Lager, Angela M.

Mayo Clinic

Cancer | December 19, 2025 | Volume: 132 | Issue: 1 | Pages: No page available

10.1002/cncr.70210 | PMID 41417597 Get It

ABSTRACT Background Isolated chromosome 5/5q losses (–5/5q) without TP53 mutations are associated with favorable outcomes in myeloid neoplasms (MN) with <5% blasts. However, the clinical implication of concurrent −5/5q and TP53 aberrations in MN with ≥5% blasts is poorly understood. Methods Patients with TP53 ‐mutated MN carrying ≥5% blasts assessing the prognostic impact of ‐5/5q on 24‐month overall survival (OS24) were examined. Results Of 587 patients, 515 (88%) exhibited −5/5q overwhelmingly in the context of a complex karyotype (98.3% vs. 61.1% complex karyotype without −5/5q; p < .0001) and multihit TP53 allelic state (88.3% vs. 56.9%; p < .0001). Proportions of patients with blasts ≥20% were comparable between groups with and without −5/5q; p = 0.26. Notably, patients with −5/5q exhibited significantly fewer coalterations; p < .0001. Looking at outcomes, presence of −5/5q was associated with shorter median 24‐month overall survival (7.8 months vs. 11.2 months; p Log‐rank = .012), an effect restricted to subgroups with blasts <20% ( p = .039; N = 163), absent −7/7q ( p = .007; N = 225), or WHO5‐defined single hit allelic state ( p = 0.030; N = 91). Importantly, −5/5q retained independent adverse prognostic significance regardless of TP53 allelic state in a multivariable model. Furthermore, among the subset of 75 (13%) patients undergoing allogeneic stem cell transplantation, −5/5q predicted significantly shorter median 5‐year posttransplant survival (16.2 months vs. median not reached; p Log‐rank = .009). Conclusions These findings emphasize the independent prognostic relevance of chromosome 5/5q losses underscoring the clinical relevance of cytogenetic testing for −5/5q even in this high‐risk cohort.
JAK2 wild-type erythrocytosis: concept, differential diagnosis, diagnostic steps, and treatment approaches
Tefferi, Ayalew, Gangat, Naseema , Szuber, Natasha , Tefferi, Ayalew

Mayo Clinic

Hematology | December 5, 2025 | Volume: 2025 | Issue: 1 | Pages: 183-190

10.1182/hematology.2025000704 | PMID 41347984 Get It

Abstract JAK2 unmutated/wild-type erythrocytosis is a prevalent condition encompassing a wide spectrum of hereditary and acquired entities. It is conventionally defined by the same hemoglobin/hematocrit thresholds as for polycythemia vera. Incidence has been reported to be between 0.13% and 4.1%. The most clinically relevant step in the workup of erythrocytosis is the exclusion of polycythemia vera through JAK2 mutation screening. Consideration of relative polycythemia, normal outliers, and the influence of erythropoietic drugs and comorbidities is also imperative. Distinguishing long-standing from newly acquired erythrocytosis further streamlines the diagnostic process. Hereditary erythrocytosis (HE) is lifelong and typically associated with a positive family history. Subnormal serum erythropoietin (EPO) suggests an EPO receptor mutation. Otherwise, oxygen tension at 50% hemoglobin saturation (p50) discerns between high oxygen-affinity hemoglobin variants, 3-bisphosphoglycerate deficiency, methemoglobinemia, and PIEZO1 mutations (low p50) and germline oxygen-sensing pathway/other rare mutations (normal p50). Acquired erythrocytosis results from hypoxia-driven factors (eg, cardiopulmonary, altitude, renal artery stenosis) and other mechanisms of EPO overproduction (eg, EPO-secreting tumors) or hypersensitivity, as well as EPO-independent mechanisms. Drugs (eg, sodium glucose co-transporter-2 inhibitors, testosterone) are also common causes. Idiopathic erythrocytosis is a diagnosis of exclusion, increasingly attributed to underlying genetic mutations/polymorphisms. There are currently no evidence-based treatment guidelines. Low-dose aspirin and/or phlebotomy (with frequency determined by symptom relief) might be considered on an individualized basis in the presence of hyperviscosity symptoms, cardiovascular comorbidities, and/or a history of thrombosis. Aggressive control of cardiovascular risk factors is recommended in all. A graphic abstract representation is provided in Figure 1.
Acute leukemia during pregnancy: A three-decade Mayo Clinic experience
Rezasoltani, Mahsa , Patnaik, Mrinal M. , Johnson, Isla McKerrow , Medina, Aldo Acosta, Al‐Kali, Aref , Begna, Kebede, Pardanani, Animesh , Khera, Nandita , Litzow, Mark R. , Tefferi, Ayalew , Gangat, Naseema , Kimball, Brittany , Saliba, Antoine N. , McCullough, Kristen , Hogan, William J. , Csizmar, Clifford M. , Alkhateeb, Hassan B.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6408-6408

10.1182/blood-2025-6408 Get It

Abstract Introduction Management of acute leukemia (AL) during pregnancy remains challenging. In the first trimester, chemotherapy is toxic to the fetus, while delaying treatment may endanger maternal health, often prompting recommendations for pregnancy termination. In later trimesters, although the risk of congenital malformations decreases, complications such as preterm labor remain prevalent. Delivery prior to chemotherapy may be considered in advanced gestation. This study aimed to describe maternal and fetal outcomes of patients diagnosed with AL during pregnancy. Methods Following institutional review board approval, we retrospectively identified pregnant patients diagnosed with AL between 1995 and 2025 across Mayo Clinic sites (Minnesota, Arizona, Florida). We recorded leukemia subtype, treatment course, maternal and fetal outcomes. Results We identified 18 patients diagnosed with AL during pregnancy, including 11 with acute myeloid leukemia (AML) and 7 with acute lymphoblastic leukemia (ALL). Ten were diagnosed in the first trimester, 3 in the second, and 5 in the third. In the AML group (n=11; median age 30 years, range 18-42), one patient had acute promyelocytic leukemia (APL). ELN 2022 risk stratification was favorable in 5 (45%), intermediate in 4 (36%), and adverse in 2 (18%). In the ALL group (n=7; median age 23 years, range 19-34), 5 had B-ALL (one Philadelphia chromosome-positive) and 2 had T-ALL. All ALL cases were diagnosed in the first trimester. Among first-trimester AMLs, 2 of 3 had core-binding factor (CBF) AML. All eight patients diagnosed in the second and third trimesters had AML (1 APL, 2 CBF AML, 1 KMT2A-rearranged, 1 with DEK::NUP214 fusion, 1 complex karyotype including t(8;21), 2 with normal karyotype). Overall, 15 (83%) patients achieved complete remission (CR) or CR with incomplete count recovery (CRi) after initial induction. One patient had refractory disease and achieved partial remission after salvage, another had refractory disease and achieved CR after multiple lines of therapy, and a third achieved CR after FLAG-idarubicin and revumenib. Five patients received chemotherapy during pregnancy (3 in the first trimester, 1 in the second, 1 in the third); two of these resulted in live births. Among the 10 patients diagnosed in the first trimester, all underwent therapeutic or spontaneous abortion. Of the 3 second-trimester diagnoses, 2 underwent spontaneous or therapeutic abortion at 15 weeks. The third received 7+3 induction at 24 weeks for KMT2A-rearranged AML, followed by preterm delivery at 26 weeks and re-induction with FLAG-idarubicin plus revumenib, achieving CR. Among the 5 third trimester diagnoses, 4 delivered preterm infants (median gestational age 33 weeks) prior to chemotherapy. One patient received 7+3 at 29 weeks and delivered a viable preterm infant at 36 weeks. At a median follow-up of 6.5 years, 5 of 11 patients with AML (45%) and 3 of 7 patients with ALL (43%) died, mostly due to disease progression. Median overall survival was not reached in either group. Causes of death were as follows: 1 of AML, 1 of ALL, 3 of acute stem cell transplant (SCT) complications, 1 of chronic SCT complications, 1 of Hodgkin lymphoma, and 1 of pneumonia. Among patients diagnosed in the second and third trimesters (n=8, all with AML), 6 (75%) resulted in live births: 5 of 5 (100%) third-trimester diagnoses and 1 of 3 (33%) second-trimester diagnoses. All received intensive induction: 7+3 (n=5), 7+3 + ATRA (n=1), 7+3 + gilteritinib (n=1), and 7+3 + nilotinib (n=1). Of the second-trimester group, only one received induction prior to delivery; she later achieved CR with FLAG-ida and revumenib. Among the third-trimester group, one patient received chemotherapy prior to delivery and achieved CR followed by SCT. All but one of the 8 AML patients achieved CR after initial therapy. Conclusions Successful pregnancy outcomes were achieved in 75% of patients diagnosed with AML during the late second or third trimester. Notably, 5 (28%) of patients received chemotherapy during pregnancy. Larger, multi-institutional cohorts are warranted to further characterize the incidence and outcomes of AL in pregnancy.